Dr. Drilon earned his medical degree from the University of the Philippines College of Medicine and completed his residency in Internal Medicine at Sinai Hospital of Baltimore. He is board-certified in Internal Medicine and Medical Oncology. Recognized with awards such as the ASCO Young Investigator Award and the MSKCC Louise and Allston Boyer Young Investigator Award, Dr. Drilon is a member of ASCO, IASLC, and AACR. His influential research on TRK fusion–positive cancers and targeted therapies has been published in prestigious journals like The New England Journal of Medicine and Cancer Discovery, significantly impacting the field of oncology.
Education
- Medical School: University of the Philippines College of Medicine
- Residency: Internal Medicine at Sinai Hospital of Baltimore
- Board Certifications: Internal Medicine, Medical Oncology
Awards
- ASCO Young Investigator Award
- IASLC Fellowship Award
- MSKCC Louise and Allston Boyer Young Investigator Award
Professional Memberships and Affiliation
- American Society of Clinical Oncology (ASCO)
- International Association for the Study of Lung Cancer (IASLC)
- American Association for Cancer Research (AACR)
Clinical Experience
Dr. Alexander Drilon is a leading medical oncologist at Memorial Sloan Kettering Cancer Center, specializing in lung cancers with rare mutations. His clinical expertise lies in precision oncology, where he focuses on identifying and targeting genetic alterations in tumors. Dr. Drilon is dedicated to offering personalized treatment options through the use of targeted therapies and is actively involved in clinical trials that explore novel agents for rare oncogenic drivers. His commitment to patient care ensures that individuals with uncommon lung cancer subtypes receive cutting-edge treatments tailored to their specific genetic profiles.
Research and Publications
- Drilon A, et al. “Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children.” The New England Journal of Medicine.
- Drilon A, et al. “A Next-Generation ALK Inhibitor, in ALK-Positive Non–Small-Cell Lung Cancer.” The New England Journal of Medicine.
- Drilon A, et al. “Response to Cabozantinib in patients with RET fusion–positive lung adenocarcinomas.” Cancer Discovery.
Dr. Alexander Drilon
Medical Oncologist
Cancer Treated:
- 1275 York Avenue, New York, NY 10065
- (646) 888-4202
Dr. Drilon earned his medical degree from the University of the Philippines College of Medicine and completed his residency in Internal Medicine at Sinai Hospital of Baltimore. He is board-certified in Internal Medicine and Medical Oncology. Recognized with awards such as the ASCO Young Investigator Award and the MSKCC Louise and Allston Boyer Young Investigator Award, Dr. Drilon is a member of ASCO, IASLC, and AACR. His influential research on TRK fusion–positive cancers and targeted therapies has been published in prestigious journals like The New England Journal of Medicine and Cancer Discovery, significantly impacting the field of oncology.